The growth of public health care expenditure is one of major concerns for health policy makers across industrialised Countries, especially in a period of recession as the present one. In the quest to control costs, public health care systems control the prices of reimbursable medicines by combining listing with several instruments ranging from external reference pricing to cost-effectiveness thresholds to value-based schemes (e.g. risk-sharing). The aim of these regulatory mechanisms is to find an optimal trade-off between the need to incentivate R&D, consumers’ protection and value for money in the use of public funds. However, the regulations and restrictions laid down by Government agencies in this sector are themselves a source of distortion. The aim of this paper is to study the effects of listing and risk-sharing in the market for new, innovative drugs. We will study the introduction of these schemes under different rules as concerns the negotiation process and risksharing arrangements. Finally, we will review the empirical evidence on the effects that regulation has on innovation.
La regolazione del prezzo del farmaco: dal listing alle formule value based
LEVAGGI, Rosella
2012-01-01
Abstract
The growth of public health care expenditure is one of major concerns for health policy makers across industrialised Countries, especially in a period of recession as the present one. In the quest to control costs, public health care systems control the prices of reimbursable medicines by combining listing with several instruments ranging from external reference pricing to cost-effectiveness thresholds to value-based schemes (e.g. risk-sharing). The aim of these regulatory mechanisms is to find an optimal trade-off between the need to incentivate R&D, consumers’ protection and value for money in the use of public funds. However, the regulations and restrictions laid down by Government agencies in this sector are themselves a source of distortion. The aim of this paper is to study the effects of listing and risk-sharing in the market for new, innovative drugs. We will study the introduction of these schemes under different rules as concerns the negotiation process and risksharing arrangements. Finally, we will review the empirical evidence on the effects that regulation has on innovation.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
